Gamida Cell to Host Virtual Pipeline Deep Dive
December 02 2020 - 8:01AM
Business Wire
- Focused on omidubicel, an advanced cell
therapy, including a review of Phase 3 clinical data, and GDA-201,
a natural killer cell therapy –
- Event to feature an omidubicel patient’s
perspective -
- Live webcast on December 9, 2020 at 8:00 a.m.
ET -
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy
company committed to cures for blood cancers and serious blood
diseases, announced today that it will host a virtual event
discussing the company’s pipeline, including omidubicel, an
advanced cell therapy in Phase 3 clinical development as a
potentially life-saving treatment option for patients in need of a
bone marrow transplant, and GDA-201, an investigational, natural
killer (NK) cell-based cancer immunotherapy, on Wednesday, December
9, 2020 at 8:00 a.m. ET.
The live event will be available at the following link. A replay
of the webcast will be available in the “Investors & Media”
section of the Gamida Cell website, www.gamida-cell.com, and will
be available for at least 14 days following the event.
About Gamida Cell
Gamida Cell is an advanced cell therapy company committed to
cures for patients with blood cancers and serious blood diseases.
We harness our cell expansion platform to create therapies with the
potential to redefine standards of care in areas of serious medical
need. For additional information, please visit www.gamida-cell.com
or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201202005565/en/
For investors: Stephanie Ascher Stern Investor Relations, Inc.
stephanie.ascher@sternir.com 1-212-362-1200
For media: Matthew Corcoran Ten Bridge Communications
mcorcoran@tenbridgecommunications.com 1-617-866-7350
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Apr 2023 to Apr 2024